NovaBridge Biosciences (NBP) Debt to Equity (2018 - 2023)

NovaBridge Biosciences (NBP) reported Debt to Equity of $0.02 for Q4 2023, up 167.77% year-over-year from $0.01 in Q4 2022, and up 37.55% quarter-over-quarter from $0.01 in Q2 2023.

NovaBridge Biosciences (NBP) Debt to Equity (2018 - 2023) Analysis & Trends

NovaBridge Biosciences (NBP) has 4 years of Debt to Equity data on file, last reported at $0.02 in Q4 2023.

  • Debt to Equity for Q4 2023 came in at $0.02, up 167.77% year-over-year; the trailing twelve-month figure through Dec 2023 was $0.02 (up 167.77% YoY), and the FY2023 annual result was $0.02, up 160.89% from the prior year.
  • Debt to Equity climbed to $0.02 in Q4 2023 per NBP's latest filing, from $0.01 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.02 in Q4 2023 and troughed at -$0.02 in Q4 2019.
  • A 3-year average of $0.0 and a median of $0.01 in 2022 frame the typical range for Debt to Equity.
  • The sharpest annual moves came in 2019 and 2023: Debt to Equity jumped 70.66% in 2019, then surged 167.77% in 2023.
  • A 3-year view of Debt to Equity shows it stood at -$0.02 in 2019, then jumped by 126.51% to $0.01 in 2022, then surged by 167.77% to $0.02 in 2023.
  • Business Quant data shows NBP's Debt to Equity at $0.02 in Q4 2023, $0.01 in Q2 2023, and $0.01 in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - -
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn 0.32
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn -
9 Abivax 90.15 Bn 90.15 Bn - -
10 NovaBridge Biosciences 328.19 Mn 117.34 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 0.02
Jun 30, 2023 0.01
Dec 31, 2022 0.01
Dec 31, 2019 -0.02
Dec 31, 2018 -0.08